EUVIMEDEUVIMED entdecken
Crossref

Late clinical and echocardiographic results with the Magna Ease© pericardial aortic bioprosthesis

Amedeo Anselmi iD, Marie Aymami, Jacques Tomasi iD, Gemma D'Alessandro, Thierry Langanay, Hervé Corbineau, Julien Mancini, Erwan Flecher, Jean-Philippe Verhoye

European Journal of Cardio-Thoracic Surgery · 01.02.2024 · 65 (2)

DOI: 10.1093/ejcts/ezad351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 24.11.2023. Verfasst von Amedeo Anselmi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Bioprosthesis, Aortic Valve Stenosis, Heart Valve Prosthesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Edwards Lifesciences Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES The population of candidates to surgical aortic valve replacement (SAVR) is evolving. The Perimount Magna Ease© bioprosthesis has been introduced relatively recently in the practice. We aimed at evaluating its long-term results. METHODS This article describes a single-centre cohort of 1016 consecutive SAVRs with the Magna Ease© valve (2008–2014), consisting of an all-comers population. We performed a prospective collection of in-hospital data, systematic clinical and echocardiographic follow-up. Valve-related events were as follows: structural valve deterioration (SVD; according to modified definition criteria), nonstructural valve dysfunction, patient–prosthesis mismatch (PPM). RESULTS Age at SAVR was 73.4 ± 9.5 years; calcified aortic stenosis was the indication to surgery in 59.6%. A total of 974 patients entered the follow-up; 564 were alive at the last follow-up (median duration: 9.8 years) (up to 13.4 years). New York Heart Association class was I or II in 92.1%. Overall survival at 10 years was 56.8 ± 1.8%. Freedom from SVD at 10 was 96.5 ± 0.8% (Kaplan–Meier) and 97.4 ± 0.6% (competing risks) (28 SVD events after 6.9 ± 3.3 years). There were 15 reinterventions for SVD (redo-SAVR and Transcatheter Aortic Valve Implantation (TAVI)); 10-year freedom from reintervention was 97.8 ± 0.6%. Moderate and severe PPM occurred in 26.8% and 5.4%, respectively, without association with late mortality (P = 0.12 for moderate and P = 0.70 for severe PPM). Freedom from valve-related mortality was 97.8 ± 0.5% at 10 years. CONCLUSIONS In this follow-up of the Magna Ease bioprosthesis for SAVR, data indicate good late outcomes (30-day outcomes are excluded). Continued follow-up is required to further support its use in patients with life expectancy >10–12 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationBioprosthesisAortic Valve StenosisHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementHumansMiddle AgedAgedAged, 80 and overProspective StudiesAortic ValveEchocardiographyTreatment OutcomeProsthesis Design

Stichwörter der Autor:innen

BioprosthesesOutcomesSurgical aortic valve replacement

Autor:innen und Institutionen

  • Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France.
  • Univ Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.
  • Aix-Marseille Univ, Inserm, IRD, ISSPAM, APHM, Biostatistics Dept, UMR1252 SESSTIM Research Unit, Marseille, France.

ORCID-Profile: Amedeo Anselmi, Jacques Tomasi

Förderung

  • Edwards Lifesciences Inc

Zitieren

APA

Anselmi, A., Aymami, M., Tomasi, J., D'Alessandro, G., Langanay, T., Corbineau, H., Mancini, J., Flecher, E., & Verhoye, J. P. (2024). Late clinical and echocardiographic results with the Magna Ease© pericardial aortic bioprosthesis. European Journal of Cardio-Thoracic Surgery, 65(2). https://doi.org/10.1093/ejcts/ezad351

Vancouver

Anselmi A, Aymami M, Tomasi J, D'Alessandro G, Langanay T, Corbineau H, et al. Late clinical and echocardiographic results with the Magna Ease© pericardial aortic bioprosthesis. European Journal of Cardio-Thoracic Surgery. 2024;65(2). doi:10.1093/ejcts/ezad351

BibTeX
@article{Anselmi2024,
  author = {Anselmi, Amedeo and Aymami, Marie and Tomasi, Jacques and D'Alessandro, Gemma and Langanay, Thierry and Corbineau, Hervé and Mancini, Julien and Flecher, Erwan and Verhoye, Jean-Philippe},
  title = {Late clinical and echocardiographic results with the Magna Ease© pericardial aortic bioprosthesis},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2024},
  volume = {65},
  number = {2},
  doi = {10.1093/ejcts/ezad351}
}
Kostenlos starten →